MedCap AB/Skr MCAP
1D1W1MYTD1Y5YMAX
Capital at risk
About MedCap AB
MedCap AB, established in 2001 and headquartered in Stockholm, Sweden, is a private equity firm specializing in the acquisition and development of small to medium-sized companies within the life sciences sector. The firm focuses on three primary business areas: MedTech, Assistive Tech, and Specialty Pharma. MedCap's portfolio includes subsidiaries such as Abilia, which operates in assistive technology; Cardiolex, specializing in ECG solutions; and Unimedic, involved in specialty pharmaceuticals. The company primarily targets investments in Northern Europe, aiming to support businesses with international growth potential. MedCap typically acquires majority stakes, providing capital, expertise, and networks to foster long-term development.
- Ticker
- Skr MCAP
- Sector
- Health
- Primary listing
- XSTO
- Employees
- 647
- Headquarters
- Stockholm, Sweden
- Website
- medcap.se/en
MedCap AB Metrics
BasicAdvanced
kr 7.8B
32.71
kr 16.07
0.49
-
Price and volume
Market cap
kr 7.8B
Beta
0.49
52-week high
kr 636.00
52-week low
kr 440.00
Average daily volume
17K
Financial strength
Current ratio
1.862
Quick ratio
1.318
Long term debt to equity
0.233
Total debt to equity
0.288
Interest coverage (TTM)
6.50%
Profitability
EBITDA (TTM)
428.9
Gross margin (TTM)
59.38%
Net profit margin (TTM)
10.66%
Operating margin (TTM)
14.05%
Effective tax rate (TTM)
23.10%
Revenue per employee (TTM)
kr 3,490,000
Management effectiveness
Return on assets (TTM)
8.15%
Return on equity (TTM)
16.36%
Valuation
Price to earnings (TTM)
32.709
Price to revenue (TTM)
3.487
Price to book
4.93
Price to tangible book (TTM)
36.53
Price to free cash flow (TTM)
24.54
Free cash flow yield (TTM)
4.08%
Free cash flow per share (TTM)
21.414
Growth
Revenue change (TTM)
18.58%
Earnings per share change (TTM)
20.81%
3-year revenue growth (CAGR)
18.88%
3-year earnings per share growth (CAGR)
17.12%
Bulls say / Bears say
On July 21, 2026, MedCap reported Q2 EPS of SEK 4.6, up from SEK 3.6 year-on-year, underscoring robust profit growth. (FT)
The firm’s trailing twelve-month revenue of SEK 2.26 billion and net income of SEK 240.70 million highlight its scale and diversified Life Science portfolio. (FT)
Analysts have a median 12-month price target of SEK 640, implying roughly 12% upside from current levels. (FT)
Trailing P/E of 35.42x suggests an elevated valuation relative to peers, reducing margin of safety. (FT)
The stock has declined 8.01% over the past year, underperforming its mid-cap peers and reflecting investor caution. (FT)
Analyst coverage is limited to just two analysts, indicating low institutional focus and potential liquidity constraints. (FT)
Data summarised monthly by Lightyear AI. Last updated on 31 Aug 2026.
Upcoming events
No upcoming events
Funds containing MedCap AB
AllEURGBPUSD
Fund name | Fund size | Skr MCAP weighting |
|---|---|---|
Xtrackers MSCI Europe Small Cap€DX2J | €3.2B | 0.04% |
Xtrackers MSCI Europe Small Cap£XXSC | £2.8B | 0.04% |
iShares MSCI World Small Cap$WSML | $9B | 0.01% |
iShares MSCI World Small Cap€IUSN | €7.8B | 0.01% |
iShares MSCI World Small Cap£WLDS | £6.7B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.